Post-herpetic neuralgia in older adults: Evidence-based approaches to clinical management

Drugs and Aging

Volumn 24, Issue 1, 2007, Pages 1-19

  Christo, Paul J ^a   Hobelmann, Greg ^a   Maine, David N ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMITRIPTYLINE; BUPRENORPHINE; CAPSAICIN; CHICKENPOX VACCINE; CORTICOSTEROID; DESIPRAMINE; DIMENHYDRINATE; EMLA; FAMCICLOVIR; FENTANYL; GABAPENTIN; LAXATIVE; LIDOCAINE; METHADONE; METHYLPREDNISOLONE; METOCLOPRAMIDE; MORPHINE; NORTRIPTYLINE; ONDANSETRON; OPIATE; OXYCODONE; PLACEBO; PREGABALIN; SCOPOLAMINE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALACICLOVIR; VARICELLA ZOSTER VACCINE;

AGING; ANALGESIA; ARACHNOIDITIS; ASEPTIC MENINGITIS; ATAXIA; BLURRED VISION; BODY EQUILIBRIUM; BURNING SENSATION; CARDIOVASCULAR DISEASE; CAUDA EQUINA SYNDROME; CELLULAR IMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RELEASE; DRUG WITHDRAWAL; FATIGUE; HEADACHE; HEART ARRHYTHMIA; HEART PALPITATION; HERPES ZOSTER; HORMONE ACTION; HUMAN; HYPERALGESIA; HYPOKALEMIA; IMMUNOREACTIVITY; MONOTHERAPY; MORBIDITY; NAUSEA; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NONHUMAN; ORTHOSTATIC HYPOTENSION; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SEDATION; SEIZURE; SEROTONIN SYNDROME; SIDE EFFECT; SKIN IRRITATION; SOMNOLENCE; SUDDEN DEATH; SYMPATHETIC BLOCKING; TORSADE DES POINTES; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VACCINATION; VARICELLA ZOSTER VIRUS; VEIN THROMBOSIS; VERTIGO; VOMITING; WEIGHT GAIN; XEROSTOMIA;

AGED; ANALGESICS; ANTIVIRAL AGENTS; CHICKENPOX VACCINE; EVIDENCE-BASED MEDICINE; HERPES ZOSTER VACCINE; HUMANS; IMMUNITY, CELLULAR; NEURALGIA, POSTHERPETIC; PAIN; RISK FACTORS;

EID: 33846425714     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200724010-00001     Document Type: Review

References (107)

1. Johnson RW, Whitton TL. Management of herpes zoster (shingles) and postherpetic neuralgia. Expert Opin Pharmacother 2004; 5 (3): 551-9
2. Douglas MW, Johnson RW, Cunningham AL. Tolerability of treatments for postherpetic neuralgia. Drug Saf 2004; 27 (15): 1217-33
3. Johnson RW, Dworkin RH. Treatment of herpes zoster and postherpetic neuralgia. BMJ 2003; 326 (7392): 748-50
4. Kinsella K, Velkoff VA. An aging world. Washington, DC: US Census Bureau: US Government Printing Office, 2001
5. Dworkin RH, Schmaker KE. The epidemiology and natural history of herpes zoster and postherpetic neuralgia. Pain Res Clin Manag 2001; 5: 39-64
6. Panlilio LM, Christo PJ, Raja SN. Current management of postherpetic neuralgia. Neurologist 2002; 8 (6): 339-50
7. Menke JJ, Heins JR. Treatment of postherpetic neuralgia. J Am Pharm Assoc (Wash) 1999; 39 (2): 217-21
8. Adams RD, Victor M, Ropper AH. Principles of neurology. New York: McGraw-Hill, 1997: 756-759
9. Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002; 59 (7): 1015-21
10. Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998; 50 (6): 1837-41
11. Eide PK, Jorum E, Stubhaug A, et al. Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: a double-blind, cross-over comparison with morphine and placebo. Pain 1994; 58 (3): 347-54
12. Weinberg JM, Scheinfeld NS. Cutaneous infections in the elderly: diagnosis and management. Dermatol Ther 2003; 16 (3): 195-205
13. Watson CP, Watt VR, Chipman M, et al. The prognosis with postherpetic neuralgia. Pain 1991. 46 (2): 195-9
14. Oaklander AL. The density of remaining nerve endings in human skin with and without postherpetic neuralgia after shingles. Pain 2001; 92 (1-2): 139-45
15. Baron R. Peripheral neuropathic pain: from mechanisms to symptoms. Clin J Pain 2000; 16 (2 Suppl.): S12-20
16. Petersen KL, Fields H, Brennum J, et al. Capsaicin evoked pain and allodynia in postherpetic neuralgia. Pain 2000; 88: 125-33
17. Rowbotham MC, Petersen KL, Fields HL. Is postherpetic neuralgia more than one disorder? Pain Forum 1998; 7: 231-7
18. Watson CP. The treatment of neuropathic pain: antidepressants and opioids. Clin J Pain 2000; 16 (2 Suppl.): S49-55
19. Bonica JJ. History of pain concepts and therapies. In: Bonica JJ, editor. The management of pain. Philadelphia (PA): Lea and Feabiger, 1990: 2-18
20. Levin MJ, Smith JG, Kaufhold RM, et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 2003; 188 (9): 1336-44
21. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352 (22): 2271-84
22. Tyring SK. Efficacy of famciclovir in the treatment of herpes zoster. Semin Dermatol 1996; 15 (2 Suppl. 1): 27-31
23. Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med 1995; 123 (2): 89-96
24. Shafran SD, Tyring SK, Ashton R, et al. Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. J Clin Virol 2004; 29 (4): 248-53
25. Beutner KR, Friedman DJ, Forszpaniak C, et al. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995 Jul; 39 (7): 1546-53
26. Tyring SK, Beutner KR, Tucker BA, et al. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med. 2000 Sep-Oct; 9 (9): 863-9
27. Gnann JW Jr, Whitley RJ. Clinical practice: herpes zoster. N Engl J Med 2002 Aug 1; 347 (5): 340-6
28. Wood J, Shukla S, Fiddian AP, et al. Treatment of acute herpes zoster: effect of early (<48 hrs) versus late (48-72 hrs) therapy with acyclovir and valaciclovir on prolonged pain. J Infect Dis 1998; 178 Suppl. 1: S81-4
29. Decroix J, Partsch H, Gonzalez R, et al. Factors influencing pain outcome in herpes zoster: an observational study with valaciclovir. J Eur Acad Dermatol Venereol 2000; 14: 23-33
30. Whitley RJ, Weiss H, Gnann JW Jr, et al. Acyclovir with and without prednisone for the treatment of herpes zoster: a randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med 1996; 125 (5): 376-83
31. Wood MJ, Johnson RW, McKendrick MW, et al. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994; 330 (13): 896-900
32. Baldessarini R. Drug therapy of depression and anxiety disorders. In: Brunton LJ, Parker KL, editors. Goodman and Gilman's pharmacological basis of therapeutics. New York: McGraw-Hill, 2006: 438-450
33. Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005; 115 (3): 254-63
34. Hempenstall K, Nurmikko TJ, Johnson RW, et al. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med 2005; 2: e164
35. Boureau F, Legallicier P, Kabir-Ahmadi M. Tramadol in postherpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Pain 2003; 104 (1-2): 323-31
36. Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomised, double-blind, placebo-controlled study. Pain 2003; 106: 151-8
37. Bernstein JE, Korman NJ, Bickers DR, et al. Topical capsaicin treatment of chronic postherpetic neuralgia. J Am Acad Dermatol 1989; 21 (2 Pt 1): 265-70
38. Collins SL, Moore RA, McQuay HJ, et al. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage 2000; 20 (6): 449-58
39. Watson CP, Vernich L, Chipman M, et al. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology 1998; 51 (4): 1166-71
40. Ahmad M, Goucke CR. Management strategies for the treatment of neuropathic pain in the elderly. Drugs Aging 2002; 19 (12): 929-45
41. Vieweg WV, Wood MA. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes. Psychosomatics 2004; 45 (5): 371-7
42. Kingery WS. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. Pain 1997; 73: 123-39
43. Potter WZ, Rudorfer MV, Manji H. The pharmacologic treatment of depression. N Engl J Med 1991 Aug 29; 325 (9): 633-42
44. McNamara J. Pharmacotherapy of the epilepsies. In: Brunton LJ, Parker KL, editors. Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill, 2006: 517-518
45. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998; 280 (21): 1837-42
46. Rice AS, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001; 94 (2): 215-24
47. Frampton JE, Foster RH. Pregabalin: in the treatment of postherpetic neuralgia. Drugs 2005; 65 (1): 111-8
48. Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003; 60 (8): 1274-83
49. Sabatowski R, Galvez R, Cherry DA, et al., the 1008-045 Study Group. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomized, placebo-controlled clinical trial. Pain 2004; 109: 26-35
50. Max MB, Schafer SC, Culnane M, et al. Association of pain relief with drug side effects in postherpetic neuralgia; a single dose study of clonidine, codeine, ibuprofen and placebo. Clin Pharmacol Ther 1988; 43: 363-71
51. Rowbotham MC, Reisner-Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 1991; 41 (7): 1024-8
52. Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. JAMA 2005; 293 (24): 3043-52
53. Rowbotham MC, Twilling L, Davies PS, et al. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003; 348 (13): 1223-32
54. Lewis JW, Husbands SM. The orvinols and related opioids-high affinity ligands with diverse efficacy profiles. Curr Pharm Des 2004; 10 (7): 717-32
55. Cowan A, Lewis JW, Macfarlane IR. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 1977; 60: 537-45
56. Lee K, Akil H, Woods JH, et al. Differential binding properties of oripavines at cloned mu and delta opioid receptors. Eur J Pharmacol 1999; 378: 323-30
57. Likar R, Sittl R. Transdermal buprenorphine for treating nociceptive and neuropathic pain: four case studies. Anesth Analg 2005; 100: 781-5
58. Likar R, Kayser H, Sittl R. Long term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow up study in patients from three short-term clinical trials. Clin Ther 2006; 28: 943-52
59. Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005; 352 (13): 1324-34
60. Bulka A, et al. Reduced tolerance to the anti-hyperalgesic effect of methadone in comparison to morphine in a rat model of mononeuropathy. Pain 2002; 95 (1-2): 103-9
61. Davis AM, Inturrisi CE. d-Methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia. J Pharmacol Exp Ther 1999; 289 (2): 1048-53
62. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med 2003; 349 (20): 1943-53
63. Rushton ARA, Sneyd JR. Opioid analgesics. Br J Hosp Med 1997; 57: 105-6
64. Raffa RB. A novel approach to the pharmacology of analgesics. Am J Med 1996; 101 Suppl. 1A: 40S-46S
65. Minto CF, Power I. New opioid analgesics: an update. Int Anesthesiol Clin 1997; 35: 49-65
66. Aronson MD. Nonsteroidal anti-inflammatory drugs, traditional opioids, and tramadol: contrasting therapies for the treatment of chronic pain. Clin Ther 1997; 19: 420-32
67. Duthie DJR. Remifentanil and tramadol. Br J Anaesth 1998; 81: 51-7
68. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998; 50 (6): 1842-6
69. Gobel H, Stadler T. Treatment of post-herpes zoster pain with tramadol. Results of an open pilot study versus clomipramine with or without levomepromazine. Drugs 1997; 53 Suppl. 2: 34-9
70. Dalgin P. Use of tramadol in chronic pain. Clin Geriatrics 1995; 3: 1-6
71. Bamigbade TA, Langford RM. Tramadol hydrochloride: an overview of current use. Hosp Med 1998; 59 (5): 373-6
72. Schug SA, Dickenson AH, Straugurger W, et al. Current concepts on the mechanisms of action of tramadol [abstract]. 9th World Congress on Pain; 1999 Aug 22-27; Vienna
73. Shipton EA. Tramadol: present and future. Anaesth Intensive Care 2000; 28 (4): 363-74
74. Gana TJ, Pascual ML, Fleming RR, et al. Extended-release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Curr Med Res Opin 2006; 22 (7): 1391-401
75. Grond S, Zech D, Lynch J, et al. Tramadol: a weak opioid for relief of cancer pain. Pain Clin 1992; 5: 241
76. Cossmann M, Wilsmann KM. Behandlung langer andauernder Schmerzsyndrome: Beurteilung der Wirkung und Vertraglichkeit von Tramadol (Tramal) bei mehrmaliger Gabe. Munch Med Wochenschr 1987; 129: 851
77. Cossmann M, Wilsmann KM. Effects and side-effects of tramadol: an open phase IV study with 7198 patients. Therapiewoche 1987; 37: 3475-85
78. Bartlett D. Serotonin syndrome: a subtle toxicity. J Emerg Nurs 2006; 32 (3): 277-9
79. Davies PS, Galer BS. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs 2004; 64 (9): 937-47
80. Rowbotham MC, Davies PS, Verkempinck C, et al. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996; 65 (1): 39-44
81. Galer BS, Rowbotham MC, Perander J, et al. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 1999; 80 (3): 533-8
82. Galer BS, Jensen MP, Ma T, et al. The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the Neuropathic Pain Scale. Clin J Pain 2002; 18 (5): 297-301
83. Rowbotham MC, Davies PS, Fields HL. Topical lidocaine gel relieves postherpetic neuralgia. Ann Neurol 1995; 37 (2): 246-53
84. Attal N, Brasseur L, Chauvin M, et al. Effects of single and repeated applications of a eutectic mixture of local anaesthetics (EMLA) cream on spontaneous and evoked pain in postherpetic neuralgia. Pain 1999; 81 (1-2): 203-9
85. Endo Pharmaceuticals Inc. Lidoderm® (lidocaine patch 5%) prescribing information. Chadds Ford (PA): Endo Pharmaceuticals Inc., 2000
86. Gimbel J, Moskowitz M, Hines R, et al. Lidocaine patch 5% effectively treats common pain qualities reported by patients with acute, subacute, and chronic low back pain [abstract]. Fifth International Conference on Mechanisms and Treatment of Neuropathic Pain; 2002 Nov 21-23, Southhampton, Bermuda
87. Burch F, Codding C, Patel N, et al. Effectiveness and safely of the lidocaine patch 5% as add on or monotherapy in patients with pain and osteoarthritis; a prospective, open-label, multicenter study [abstract]. Fifth International Conference on the Mechanisms and Treatment of Neuropathic Pain; 2002 Nov 21-23, Southhampton, Bermuda
88. Lincoff NS, Rath PP, Hirano M. The treatment of periocular and facial pain with topical capsaicin. J Neuroophthalmol 1998; 18 (1): 17-20
89. Rumsfield JA, West DP. Topical capsaicin in dermatologic and peripheral pain disorders. DICP 1991; 25 (4): 381-7
90. Fusco BM, Giacovazzo M. Peppers and pain: the promise of capsaicin. Drugs 1997; 53 (6): 909-14
91. Nolano M, Simone DA, Wendelschafer-Crabb G, et al. Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain 1999; 81 (1-2): 135-45
92. Watson CP, Tyler KL, Bickers DR, et al. A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther 1993; 15 (3): 510-26
93. Parsons CG. NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol 2001; 429: 71-8
94. Siddall PJ, Cousins MJ. Persistent pain as a disease entity: implications for clinical management. Anesth Analg 2004; 99 (2): 510-20
95. Eide K, Stubhaug A, Oye I, et al. Continuous subcutaneous administration of the N-methyl-D-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia. Pain 1995; 61 (2): 221-8
96. Quan D, Wellish M, Gilden DH. Topical ketamine treatment of postherpetic neuralgia. Neurology 2003; 60 (8): 1391-2
97. Klepstad P, Borchgrevink PC. Four years' treatment with ketamine and a trial of dextromethorphan in a patient with severe post-herpetic neuralgia. Acta Anaesthesiol Scand 1997; 41 (3): 422-6
98. Hoffmann V, Coppejans H, Vercauteren M, et al. Successful treatment of postherpetic neuralgia with oral ketamine. Clin J Pain 1994; 10 (3): 240-2
99. Kotani N, Kushikata T, Hashimoto H, et al. Intrathecal methylprednisolone for intractable postherpetic neuralgia. N Engl J Med 2000; 343 (21): 1514-9
100. Nelson DA. Intraspinal therapy using methylprednisolone acetate: twenty-three years of clinical controversy. Spine 1993; 18 (2): 278-86
101. Abram SE. Intrathecal steroid injection for postherpetic neuralgia: what are the risks? Reg Anesth Pain Med 1999; 24 (4): 283-5
102. Kikuchi A, Kotani N, Sato T, et al. Comparative therapeutic evaluation of intrathecal versus epidural methylprednisolone for long-term analgesia in patients with intractable postherpetic neuralgia. Reg Anesth Pain Med 1999; 24 (4): 287-93
103. Wu CL, Marsh A, Dworkin RH. The role of sympathetic nerve blocks in herpes zoster and postherpetic neuralgia. Pain 2000; 87 (2): 121-9
104. Opstelten W, van Wijck AJ, Stolker RJ. Interventions to prevent postherpetic neuralgia: cutaneous and percutaneous techniques. Pain 2004; 107 (3): 202-6
105. Loeser J. Surgery for postherpetic neuralgia. In: Watson CP, editor. Herpes zoster and postherpetic neuralgia. Amsterdam: Elsevier, 1993: 221-37
106. Meglio M, Cioni B, Prezioso A, et al. Spinal cord stimulation (SCS) in the treatment of postherpetic pain. Acta Neurochir Suppl (Wien) 1989; 46: 65-6
107. Harke H, Gretenkort P, Ladleif HU, et al. Spinal cord stimulation in postherpetic neuralgia and in acute herpes zoster pain. Anesth Analg 2002; 94 (3): 694-700